Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK p.Gly1202Arg (p.G1202R) ALK p.Gly1202Arg (p.G1202R)
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reported for alectinib on Ba/F3 with EML4-ALK wild-type. Similar experiments using NPM-ALK instead of EML4-ALK yielded survival IC50 of 549 nM of NPM-ALK G1202R to alectinib, which was 27.9 times higher than IC50 for NPM-ALK wild-type. Western blots of Ba/F3 with NPM-ALK wild-type showed ablation of pALK levels above 100 nM alectinib, while pALK levels were essentially unchanged up to 1000 nM in NPM-ALK G1202R Ba/F3 cells.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1350
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/171
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Alectinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 25727400
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Alectinib | Resitance or Non-Reponse | true |